Showing results (71-80 of 87) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group BD M Savarese, S Halabi, V Hars, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancerY J Ko, E J Small, F Kabbinavar, et al.The Journal of Urology|November 1, 1996
Radiotherapy for high grade clinically localized adenocarcinoma of the prostateM Roach, S Meehan, S Kroll, et al.Cancer Research|April 6, 2001
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B studyR A Bok, S Halabi, D T Fei, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207J E Rosenberg, S Halabi, B L Sanford, et al.Oncogene|June 15, 1995
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cellsR J Pietras, J Arboleda, D M Reese, et al.Oncogene|January 9, 1997
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11bC A Wilson, M N Payton, G S Elliott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisoneE J Small, M Meyer, M E Marshall, et al.Cancer Research|July 1, 1996
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotypingM L Cher, G S Bova, D H Moore, et al.The Journal of Urology|May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeP F Schellhammer, P Venner, G P Haas, et al.Pageof 9